sur Jaguar Health, Inc. (NASDAQ:JAGX)
Jaguar Health Shows 20% Revenue Growth in 2024
Jaguar Health, Inc. has announced a 20% increase in net revenue for 2024 compared to 2023. The company reported total net revenue of approximately $11.7 million, up from $9.8 million in the previous year. This growth was driven by both prescription and non-prescription products.
In the fourth quarter of 2024, Jaguar's revenue reached approximately $3.5 million, marking a 13% increase over Q3 2024 and a 53% rise compared to Q4 2023. The prescription segment, including products Mytesi, Gelclair, and Canalevia-CA1, saw revenue of $3.5 million in Q4 2024.
Looking forward, Jaguar anticipates results from trials of crofelemer for rare diseases in Q2 2025. The company plans to meet with the FDA in the same quarter, following Phase 3 trial outcomes in breast cancer patients.
R. H.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Jaguar Health, Inc.